Janux Therapeutics Announces Collaboration And Exclusive Worldwide License Agreement With Bristol Myers Squibb To Develop Undisclosed Tumor-Activated Therapeutics For Solid Tumors

Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. Under the terms of the agreement, the companies will develop an undisclosed, novel, tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types.